Murphy & Mullick Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.28K	Hold	275	–	–	0.01%	497
2026 Q1	$7.99K	Hold	275	–	–	0.01%	496
2025 Q4	$7.2K	Hold	275	–	–	0.01%	514
2025 Q3	$6.93K	Hold	275	–	–	0.01%	509
2025 Q2	$5.64K	Hold	275	–	–	﹤0.01%	508
2025 Q1	$5.63K	Hold	275	–	–	0.01%	496
2024 Q4	$6.22K	Buy	+275	New	+$6.6K	0.01%	488

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Murphy & Mullick Capital Management's IDNA Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its iShares Genomics Immunology and Healthcare ETF (IDNA) position steady in Q2 2026 at 275 shares worth $9.28K. The position accounts for 0.01% of the portfolio, ranked #497.

Murphy & Mullick Capital Management first reported a position in IDNA in Q4 2024 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Murphy & Mullick Capital Management held 275 shares of iShares Genomics Immunology and Healthcare ETF worth $9.28K as of Q2 2026.
Murphy & Mullick Capital Management left its iShares Genomics Immunology and Healthcare ETF share count unchanged in Q2 2026.
iShares Genomics Immunology and Healthcare ETF made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #497 holding.
Murphy & Mullick Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2024 and has held it in 7 quarters since.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.